Cytochrome P450

Short description: Class of enzymes

Cytochrome P450

Structure of lanosterol 14α-demethylase (CYP51)

Identifiers
Symbol| p450
Pfam| PF00067
InterPro| IPR001128
PROSITE| PDOC00081
SCOP2| 2cpp / SCOPe / SUPFAM
OPM superfamily| 39
OPM protein| 2bdm
CDD| cd00302
Membranome| 265
| Available protein structures:

Pfam | structures / ECOD
PDB| RCSB PDB; PDBe; PDBj
PDBsum| structure summary

Cytochromes P450 (P450s or CYPs) are a superfamily of enzymes containing heme as a cofactor that mostly, but not exclusively, function as monooxygenases.[1][2][3] In mammals, these proteins oxidize steroids, fatty acids, and xenobiotics, and are important for the clearance of various compounds, as well as for hormone synthesis and breakdown. In 1963, Estabrook, Cooper, and Rosenthal described the role of CYP as a catalyst in steroid hormone synthesis and drug metabolism. In plants, these proteins are important for the biosynthesis of defensive compounds, fatty acids, and hormones.[2]

P450 enzymes have been identified in all kingdoms of life: animals, plants, fungi, protists, bacteria, and archaea, as well as in viruses.[4] However, they are not omnipresent; for example, they have not been found in Escherichia coli.[3][5] As of 2018[update], more than 300,000 distinct CYP proteins are known.[6][7]

P450s are, in general, the terminal oxidase enzymes in electron transfer chains, broadly categorized as P450-containing systems. The term "P450" is derived from the spectrophotometric peak at the wavelength of the absorption maximum of the enzyme (450 nm) when it is in the reduced state and complexed with carbon monoxide. Most P450s require a protein partner to deliver one or more electrons to reduce the iron (and eventually molecular oxygen).

## Contents

* 1 Nomenclature
* 2 Classification
* 3 Mechanism
* 3.1 Structure
* 3.2 Catalytic cycle
* 3.3 Spectroscopy
* 4 P450s in humans
* 4.1 Drug metabolism
* 4.1.1 Drug interaction
* 4.1.2 Interaction of other substances
* 4.2 Other specific P450 functions
* 4.2.1 Steroid hormones
* 4.2.2 Polyunsaturated fatty acids and eicosanoids
* 4.3 CYP families in humans
* 5 P450s in other species
* 5.1 Animals
* 5.2 Microbial
* 5.3 Fungi
* 5.4 Plants
* 6 P450s in biotechnology
* 7 InterPro subfamilies
* 8 See also
* 9 References
* 10 Further reading
* 11 External links

## Nomenclature

Genes encoding P450 enzymes, and the enzymes themselves, are designated with the root symbol CYP for the superfamily, followed by a number indicating the gene family, a capital letter indicating the subfamily, and another numeral for the individual gene. The convention is to italicise the name when referring to the gene. For example, CYP2E1 is the gene that encodes the enzyme CYP2E1—one of the enzymes involved in paracetamol (acetaminophen) metabolism. The CYP nomenclature is the official naming convention, although occasionally CYP450 or CYP450 is used synonymously. These names should never be used as according to the nomenclature convention (as they denote a P450 in family number 450). However, some gene or enzyme names for P450s are also referred to by historical names (e.g. P450BM3 for CYP102A1) or functional names, denoting the catalytic activity and the name of the compound used as substrate. Examples include CYP5A1, thromboxane A2 synthase, abbreviated to TBXAS1 (ThromBoXane A2 Synthase 1), and CYP51A1, lanosterol 14-α-demethylase, sometimes unofficially abbreviated to LDM according to its substrate (Lanosterol) and activity (DeMethylation).[8]

The current nomenclature guidelines suggest that members of new CYP families share at least 40% amino-acid identity, while members of subfamilies must share at least 55% amino-acid identity. Nomenclature committees assign and track both base gene names (Cytochrome P450 Homepage ) and allele names (CYP Allele Nomenclature Committee).[9][10]

## Classification

Main article: Biology:P450-containing systems

Based on the nature of the electron transfer proteins, P450s can be classified into several groups:[11]

Microsomal P450 systems
in which electrons are transferred from NADPH via cytochrome P450 reductase (variously CPR, POR, or CYPOR). Cytochrome b5 (cyb5) can also contribute reducing power to this system after being reduced by cytochrome b5 reductase (CYB5R).
Mitochondrial P450 systems
which employ adrenodoxin reductase and adrenodoxin to transfer electrons from NADPH to P450.
Bacterial P450 systems
which employ a ferredoxin reductase and a ferredoxin to transfer electrons to P450.
CYB5R/cyb5/P450 systems
in which both electrons required by the CYP come from cytochrome b5.
FMN/Fd/P450 systems
originally found in Rhodococcus species, in which a FMN-domain-containing reductase is fused to the CYP.
P450 only systems
which do not require external reducing power. Notable ones include thromboxane synthase (CYP5), prostacyclin synthase (CYP8), and CYP74A (allene oxide synthase).

The most common reaction catalyzed by cytochromes P450 is a monooxygenase reaction, e.g., insertion of one atom of oxygen into the aliphatic position of an organic substrate (RH), while the other oxygen atom is reduced to water:

RH + O2 \+ NADPH + H+ → ROH + H2O + NADP+

Many hydroxylation reactions (insertion of hydroxyl groups) use CYP enzymes.

## Mechanism

The "Fe(V) intermediate" at the bottom left is a simplification: it is an Fe(IV) with a radical heme ligand.

### Structure

The active site of cytochrome P450 contains a heme-iron center. The iron is tethered to the protein via a cysteine thiolate ligand. This cysteine and several flanking residues are highly conserved in known P450s, and have the formal PROSITE signature consensus pattern [FW] - [SGNH] - x - [GD] - {F} - [RKHPT] - {P} - C \- [LIVMFAP] - [GAD].[12] Because of the vast variety of reactions catalyzed by P450s, the activities and properties of the many P450s differ in many aspects. In general, the P450 catalytic cycle proceeds as follows:

### Catalytic cycle

1. Substrate binds in proximity to the heme group, on the side opposite to the axial thiolate. Substrate binding induces a change in the conformation of the active site, often displacing a water molecule from the distal axial coordination position of the heme iron,[13] and changing the state of the heme iron from low-spin to high-spin.[14]
2. Substrate binding induces electron transfer from NAD(P)H via cytochrome P450 reductase or another associated reductase.[15]
3. Molecular oxygen binds to the resulting ferrous heme center at the distal axial coordination position, initially giving a dioxygen adduct similar to oxy-myoglobin.
4. A second electron is transferred, from either cytochrome P450 reductase, ferredoxins, or cytochrome b5, reducing the Fe-O2 adduct to give a short-lived peroxo state.
5. The peroxo group formed in step 4 is rapidly protonated twice, releasing one molecule of water and forming the highly reactive species referred to as P450 Compound 1 (or just Compound I). This highly reactive intermediate was isolated in 2010,[16] P450 Compound 1 is an iron(IV) oxo (or ferryl) species with an additional oxidizing equivalent delocalized over the porphyrin and thiolate ligands. Evidence for the alternative perferryl iron(V)-oxo[13] is lacking.[16]
6. Depending on the substrate and enzyme involved, P450 enzymes can catalyze any of a wide variety of reactions. A hypothetical hydroxylation is shown in this illustration. After the product has been released from the active site, the enzyme returns to its original state, with a water molecule returning to occupy the distal coordination position of the iron nucleus.

File:FeIVO 2.tif

1. An alternative route for mono-oxygenation is via the "peroxide shunt" (path "S" in figure). This pathway entails oxidation of the ferric-substrate complex with oxygen-atom donors such as peroxides and hypochlorites.[17] A hypothetical peroxide "XOOH" is shown in the diagram.

### Spectroscopy

Binding of substrate is reflected in the spectral properties of the enzyme, with an increase in absorbance at 390 nm and a decrease at 420 nm. This can be measured by difference spectroscopies and is referred to as the "type I" difference spectrum (see inset graph in figure). Some substrates cause an opposite change in spectral properties, a "reverse type I" spectrum, by processes that are as yet unclear. Inhibitors and certain substrates that bind directly to the heme iron give rise to the type II difference spectrum, with a maximum at 430 nm and a minimum at 390 nm (see inset graph in figure). If no reducing equivalents are available, this complex may remain stable, allowing the degree of binding to be determined from absorbance measurements in vitro[17] C: If carbon monoxide (CO) binds to reduced P450, the catalytic cycle is interrupted. This reaction yields the classic CO difference spectrum with a maximum at 450 nm. However, the interruptive and inhibitory effects of CO varies upon different CYPs such that the CYP3A family is relatively less affected.[18]

## P450s in humans

Human P450s are primarily membrane-associated proteins[19] located either in the inner membrane of mitochondria or in the endoplasmic reticulum of cells. P450s metabolize thousands of endogenous and exogenous chemicals. Some P450s metabolize only one (or a very few) substrates, such as CYP19 (aromatase), while others may metabolize multiple substrates. Both of these characteristics account for their central importance in medicine. Cytochrome P450 enzymes are present in most tissues of the body, and play important roles in hormone synthesis and breakdown (including estrogen and testosterone synthesis and metabolism), cholesterol synthesis, and vitamin D metabolism. Cytochrome P450 enzymes also function to metabolize potentially toxic compounds, including drugs and products of endogenous metabolism such as bilirubin, principally in the liver.

The Human Genome Project has identified 57 human genes coding for the various cytochrome P450 enzymes.[20]

### Drug metabolism

Proportion of antifungal drugs metabolized by different families of P450s.[21]

Further information: Biology:Drug metabolism

P450s are the major enzymes involved in drug metabolism, accounting for about 75% of the total metabolism.[22] Most drugs undergo deactivation by P450s, either directly or by facilitated excretion from the body. However, many substances are bioactivated by P450s to form their active compounds like the antiplatelet drug clopidogrel and the opiate codeine.

#### Drug interaction

Many drugs may increase or decrease the activity of various P450 isozymes either by inducing the biosynthesis of an isozyme (enzyme induction) or by directly inhibiting the activity of the P450 (enzyme inhibition). A classical example includes anti-epileptic drugs, such as phenytoin, which induces CYP1A2, CYP2C9, CYP2C19, and CYP3A4.

Effects on P450 isozyme activity are a major source of adverse drug interactions, since changes in P450 enzyme activity may affect the metabolism and clearance of various drugs. For example, if one drug inhibits the P450-mediated metabolism of another drug, the second drug may accumulate within the body to toxic levels. Hence, these drug interactions may necessitate dosage adjustments or choosing drugs that do not interact with the P450 system. Such drug interactions are especially important to consider when using drugs of vital importance to the patient, drugs with significant side-effects, or drugs with a narrow therapeutic index, but any drug may be subject to an altered plasma concentration due to altered drug metabolism.

Many substrates for CYP3A4 are drugs with a narrow therapeutic index, such as amiodarone[23] or carbamazepine.[24] Because these drugs are metabolized by CYP3A4, the mean plasma levels of these drugs may increase because of enzyme inhibition or decrease because of enzyme induction.

#### Interaction of other substances

Naturally occurring compounds may also induce or inhibit P450 activity. For example, bioactive compounds found in grapefruit juice and some other fruit juices, including bergamottin, dihydroxybergamottin, and paradicin-A, have been found to inhibit CYP3A4-mediated metabolism of certain medications, leading to increased bioavailability and, thus, the strong possibility of overdosing.[25] Because of this risk, avoiding grapefruit juice and fresh grapefruits entirely while on drugs is usually advised.[26]

Other examples:

* Saint-John's wort, a common herbal remedy induces CYP3A4, but also inhibits CYP1A1, CYP1B1.[27][28]
* Tobacco smoking induces CYP1A2 (example CYP1A2 substrates are clozapine, olanzapine, and fluvoxamine)[29]
* At relatively high concentrations, starfruit juice has also been shown to inhibit CYP2A6 and other P450s.[30] Watercress is also a known inhibitor of the cytochrome P450 CYP2E1, which may result in altered drug metabolism for individuals on certain medications (e.g., chlorzoxazone).[31]
* Tributyltin has been found to inhibit the function of cytochrome P450, leading to masculinization of mollusks.[32]
* Goldenseal, with its two notable alkaloids berberine and hydrastine, has been shown to alter P450-marker enzymatic activities (involving CYP2C9, CYP2D6, and CYP3A4).[33]

### Other specific P450 functions

#### Steroid hormones

Steroidogenesis, showing many of the enzyme activities that are performed by cytochrome P450 enzymes.[34] HSD: Hydroxysteroid dehydrogenase.

A subset of cytochrome P450 enzymes play important roles in the synthesis of steroid hormones (steroidogenesis) by the adrenals, gonads, and peripheral tissue:

* CYP11A1 (also known as P450scc or P450c11a1) in adrenal mitochondria affects "the activity formerly known as 20,22-desmolase" (steroid 20α-hydroxylase, steroid 22-hydroxylase, cholesterol side-chain scission).
* CYP11B1 (encoding the protein P450c11β) found in the inner mitochondrial membrane of adrenal cortex has steroid 11β-hydroxylase, steroid 18-hydroxylase, and steroid 18-methyloxidase activities.
* CYP11B2 (encoding the protein P450c11AS), found only in the mitochondria of the adrenal zona glomerulosa, has steroid 11β-hydroxylase, steroid 18-hydroxylase, and steroid 18-methyloxidase activities.
* CYP17A1, in endoplasmic reticulum of adrenal cortex has steroid 17α-hydroxylase and 17,20-lyase activities.
* CYP21A2 (P450c21) in adrenal cortex conducts 21-hydroxylase activity.
* CYP19A (P450arom, aromatase) in endoplasmic reticulum of gonads, brain, adipose tissue, and elsewhere catalyzes aromatization of androgens to estrogens.

#### Polyunsaturated fatty acids and eicosanoids

Certain cytochrome P450 enzymes are critical in metabolizing polyunsaturated fatty acids (PUFAs) to biologically active, intercellular cell signaling molecules (eicosanoids) and/or metabolize biologically active metabolites of the PUFA to less active or inactive products. These CYPs possess cytochrome P450 omega hydroxylase and/or epoxygenase enzyme activity.

* CYP1A1, CYP1A2, and CYP2E1 metabolize endogenous PUFAs to signaling molecules: they metabolize arachidonic acid (i.e. AA) to 19-hydroxyeicosatetraenoic acid (i.e. 19-HETE; see 20-hydroxyeicosatetraenoic acid); eicosapentaenoic acid (i.e. EPA) to epoxyeicosatetraenoic acids (i.e. EEQs); and docosahexaenoic acid (i.e. DHA) to epoxydocosapentaenoic acids (i.e. EDPs).
* CYP2C8, CYP2C9, CYP2C18, CYP2C19, and CYP2J2 metabolize endogenous PUFAs to signaling molecules: they metabolize AA to epoxyeicosatetraenoic acids (i.e. EETs); EPA to EEQs; and DHA to EDPs.
* CYP2S1 metabolizes PUFA to signaling molecules: it metabolizes AA to EETs and EPA to EEQs.
* CYP3A4 metabolizes AA to EET signaling molecules.
* CYP4A11 metabolizes endogenous PUFAs to signaling molecules: it metabolizes AA to 20-HETE and EETs; it also hydroxylates DHA to 22-hydroxy-DHA (i.e. 12-HDHA).
* CYP4F2, CYP4F3A, and CYP4F3B (see CYP4F3 for latter two CYPs) metabolize PUFAs to signaling molecules: they metabolizes AA to 20-HETE. They also metabolize EPA to 19-hydroxyeicosapentaenoic acid (19-HEPE) and 20-hydroxyeicosapentaenoic acid (20-HEPE) as well as metabolize DHA to 22-HDA. They also inactivate or reduce the activity of signaling molecules: they metabolize leukotriene B4 (LTB4) to 20-hydroxy-LTB4, 5-hydroxyeicosatetraenoic acid (5-HETE) to 5,20-diHETE, 5-oxo-eicosatetraenoic acid (5-oxo-ETE) to 5-oxo,20-hydroxy-ETE, 12-hydroxyeicosatetraenoic acid (12-HETE) to 12,20-diHETE, EETs to 20-hydroxy-EETs, and lipoxins to 20-hydroxy products.
* CYP4F8 and CYP4F12 metabolize PUFAs to signaling molecules: they metabolizes EPA to EEQs and DHA to EDPs. They also metabolize AA to 18-hydroxyeicosatetraenoic acid (18-HETE) and 19-HETE.
* CYP4F11 inactivates or reduces the activity of signaling molecules: it metabolizes LTB4 to 20-hydroxy-LTB4, (5-HETE) to 5,20-diHETE, (5-oxo-ETE) to 5-oxo,20-hydroxy-ETE, (12-HETE) to 12,20-diHETE, EETs to 20-hydroxy-EETs, and lipoxins to 20-hydroxy products.
* CYP4F22 ω-hydroxylates extremely long "very long chain fatty acids", i.e. fatty acids that are 28 or more carbons long. The ω-hydroxylation of these special fatty acids is critical to creating and maintaining the skin's water barrier function; autosomal recessive inactivating mutations of CYP4F22 are associated with the Lamellar ichthyosis subtype of Congenital ichthyosiform erythrodema in humans.[35]

### CYP families in humans

Humans have 57 genes and more than 59 pseudogenes divided among 18 families of cytochrome P450 genes and 43 subfamilies.[36] This is a summary of the genes and of the proteins they encode. See the homepage of the cytochrome P450 Nomenclature Committee for detailed information.[20]

Family | Function | Members | Genes | Pseudogenes

|
|
|
|

CYP1 | drug and steroid (especially estrogen) metabolism, benzo[a]pyrene toxification (forming (+)-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide) | 3 subfamilies, 3 genes, 1 pseudogene | CYP1A1, CYP1A2, CYP1B1 | CYP1D1P
CYP2 | drug and steroid metabolism | 13 subfamilies, 16 genes, 16 pseudogenes | CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2F1, CYP2J2, CYP2R1, CYP2S1, CYP2U1, CYP2W1 | Too many to list
CYP3 | drug and steroid (including testosterone) metabolism | 1 subfamily, 4 genes, 4 pseudogenes | CYP3A4, CYP3A5, CYP3A7, CYP3A43 | CYP3A51P, CYP3A52P, CYP3A54P, CYP3A137P
CYP4 | arachidonic acid or fatty acid metabolism | 6 subfamilies, 12 genes, 10 pseudogenes | CYP4A11, CYP4A22, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4F22, CYP4V2, CYP4X1, CYP4Z1 | Too many to list
CYP5 | thromboxane A2 synthase | 1 subfamily, 1 gene | CYP5A1 |
CYP7 | bile acid biosynthesis 7-alpha hydroxylase of steroid nucleus | 2 subfamilies, 2 genes | CYP7A1, CYP7B1 |
CYP8 | varied | 2 subfamilies, 2 genes | CYP8A1 (prostacyclin synthase), CYP8B1 (bile acid biosynthesis) |
CYP11 | steroid biosynthesis | 2 subfamilies, 3 genes | CYP11A1, CYP11B1, CYP11B2 |
CYP17 | steroid biosynthesis, 17-alpha hydroxylase | 1 subfamily, 1 gene | CYP17A1 |
CYP19 | steroid biosynthesis: aromatase synthesizes estrogen | 1 subfamily, 1 gene | CYP19A1 |
CYP20 | unknown function | 1 subfamily, 1 gene | CYP20A1 |
CYP21 | steroid biosynthesis | 1 subfamilies, 1 gene, 1 pseudogene | CYP21A2 | CYP21A1P
CYP24 | vitamin D degradation | 1 subfamily, 1 gene | CYP24A1 |
CYP26 | retinoic acid hydroxylase | 3 subfamilies, 3 genes | CYP26A1, CYP26B1, CYP26C1 |
CYP27 | varied | 3 subfamilies, 3 genes | CYP27A1 (bile acid biosynthesis), CYP27B1 (vitamin D3 1-alpha hydroxylase, activates vitamin D3), CYP27C1 (vitamin A1 to A2) |
CYP39 | 7-alpha hydroxylation of 24-hydroxycholesterol | 1 subfamily, 1 gene | CYP39A1 |
CYP46 | cholesterol 24-hydroxylase | 1 subfamily, 1 gene, 1 pseudogene | CYP46A1 | CYP46A4P
CYP51 | cholesterol biosynthesis | 1 subfamily, 1 gene, 3 pseudogenes | CYP51A1 (lanosterol 14-alpha demethylase) | CYP51P1, CYP51P2, CYP51P3

## P450s in other species

### Animals

Other animals often have more P450 genes than humans do. Reported numbers range from 35 genes in the sponge Amphimedon queenslandica to 235 genes in the cephalochordate Branchiostoma floridae.[37] Mice have genes for 101 P450s, and sea urchins have even more (perhaps as many as 120 genes).[38] Most CYP enzymes are presumed to have monooxygenase activity, as is the case for most mammalian CYPs that have been investigated (except for, e.g., CYP19 and CYP5). Gene and genome sequencing is far outpacing biochemical characterization of enzymatic function, though many genes with close homology to CYPs with known function have been found, giving clues to their functionality.

The classes of P450s most often investigated in non-human animals are those either involved in development (e.g., retinoic acid or hormone metabolism) or involved in the metabolism of toxic compounds (such as heterocyclic amines or polyaromatic hydrocarbons). Often there are differences in gene regulation or enzyme function of P450s in related animals that explain observed differences in susceptibility to toxic compounds (ex. canines' inability to metabolize xanthines such as caffeine). Some drugs undergo metabolism in both species via different enzymes, resulting in different metabolites, while other drugs are metabolized in one species but excreted unchanged in another species. For this reason, one species's reaction to a substance is not a reliable indication of the substance's effects in humans. A species of Sonoran Desert Drosophila that uses an upregulated expression of the CYP28A1 gene for detoxification of cacti rot is Drosophila mettleri. Flies of this species have adapted an upregulation of this gene due to exposure of high levels of alkaloids in host plants.

P450s have been extensively examined in mice, rats, dogs, and less so in zebrafish, in order to facilitate use of these model organisms in drug discovery and toxicology. Recently P450s have also been discovered in avian species, in particular turkeys, that may turn out to be a useful model for cancer research in humans.[39] CYP1A5 and CYP3A37 in turkeys were found to be very similar to the human CYP1A2 and CYP3A4 respectively, in terms of their kinetic properties as well as in the metabolism of aflatoxin B1.[40]

CYPs have also been heavily studied in insects, often to understand pesticide resistance. For example, CYP6G1 is linked to insecticide resistance in DDT-resistant Drosophila melanogaster[41] and CYP6M2 in the mosquito malaria vector Anopheles gambiae is capable of directly metabolizing pyrethroids.[42]

### Microbial

Microbial cytochromes P450 are often soluble enzymes and are involved in diverse metabolic processes. In bacteria the distribution of P450s is very variable with many bacteria having no identified P450s (e.g. E.coli). Some bacteria, predominantly actinomycetes, have numerous P450s (e.g.,[43][44]). Those so far identified are generally involved in either biotransformation of xenobiotic compounds (e.g. CYP105A1 from Streptomyces griseolus metabolizes sulfonylurea herbicides to less toxic derivatives,[45]) or are part of specialised metabolite biosynthetic pathways (e.g. CYP170B1 catalyses production of the sesquiterpenoid albaflavenone in Streptomyces albus[46]). Although no P450 has yet been shown to be essential in a microbe, the CYP105 family is highly conserved with a representative in every streptomycete genome sequenced so far.[47] Due to the solubility of bacterial P450 enzymes, they are generally regarded as easier to work with than the predominantly membrane bound eukaryotic P450s. This, combined with the remarkable chemistry they catalyse, has led to many studies using the heterologously expressed proteins in vitro. Few studies have investigated what P450s do in vivo, what the natural substrate(s) are and how P450s contribute to survival of the bacteria in the natural environment.Three examples that have contributed significantly to structural and mechanistic studies are listed here, but many different families exist.

* Cytochrome P450 cam (CYP101A1) originally from Pseudomonas putida has been used as a model for many cytochromes P450 and was the first cytochrome P450 three-dimensional protein structure solved by X-ray crystallography. This enzyme is part of a camphor-hydroxylating catalytic cycle consisting of two electron transfer steps from putidaredoxin, a 2Fe-2S cluster-containing protein cofactor.
* Cytochrome P450 eryF (CYP107A1) originally from the actinomycete bacterium Saccharopolyspora erythraea is responsible for the biosynthesis of the antibiotic erythromycin by C6-hydroxylation of the macrolide 6-deoxyerythronolide B.
* Cytochrome P450 BM3 (CYP102A1) from the soil bacterium Bacillus megaterium catalyzes the NADPH-dependent hydroxylation of several long-chain fatty acids at the ω–1 through ω–3 positions. Unlike almost every other known CYP (except CYP505A1, cytochrome P450 foxy), it constitutes a natural fusion protein between the CYP domain and an electron donating cofactor. Thus, BM3 is potentially very useful in biotechnological applications.[48][49]
* Cytochrome P450 119 (CYP119A1) isolated from the thermophillic archea Sulfolobus solfataricus [50] has been used in a variety of mechanistic studies.[16] Because thermophillic enzymes evolved to function at high temperatures, they tend to function more slowly at room temperature (if at all) and are therefore excellent mechanistic models.

### Fungi

The commonly used azole class antifungal drugs work by inhibition of the fungal cytochrome P450 14α-demethylase. This interrupts the conversion of lanosterol to ergosterol, a component of the fungal cell membrane. (This is useful only because humans' P450 have a different sensitivity; this is how this class of antifungals work.)[51]

Significant research is ongoing into fungal P450s, as a number of fungi are pathogenic to humans (such as Candida yeast and Aspergillus) and to plants.

Cunninghamella elegans is a candidate for use as a model for mammalian drug metabolism.

### Plants

Cytochromes P450 are involved in a variety of processes of plant growth, development, and defense. It is estimated that P450 genes make up approximately 1% of the plant genome.[52][53] These enzymes lead to various fatty acid conjugates, plant hormones, secondary metabolites, lignins, and a variety of defensive compounds.[54]

Cytochromes P450 play an important role in plant defense– involvement in phytoalexin biosynthesis, hormone metabolism, and biosynthesis of diverse secondary metabolites.[55] The expression of cytochrome p450 genes is regulated in response to environmental stresses indicative of a critical role in plant defense mechanisms.[56]

Phytoalexins have shown to be important in plant defense mechanisms as they are antimicrobial compounds produced by plants in response to plant pathogens. Phytoalexins are not pathogen-specific, but rather plant-specific; each plant has its own unique set of phytoalexins. However, they can still attack a wide range of different pathogens. Arabidopsis is a plant closely related to cabbage and mustard and produces the phytoalexin camalexin. Camalexin originates from tryptophan and its biosynthesis involves five cytochrome P450 enzymes. The five cytochrome P450 enzymes include CYP79B2, CYP79B3, CYP71A12, CYP71A13, and CYP71B15. The first step of camalexin biosynthesis produces indole-3-acetaldoxime (IAOx) from tryptophan and is catalyzed by either CYP79B2 or CYP79B3. IAOx is then immediately converted to indole-3-acetonitrile (IAN) and is controlled by either CYP71A13 or its homolog CYP71A12. The last two steps of the biosynthesis pathway of camalexin are catalyzed by CYP71B15. In these steps, indole-3-carboxylic acid (DHCA) is formed from cysteine-indole-3-acetonitrile (Cys(IAN)) followed by the biosynthesis of camalexin. There are some intermediate steps within the pathway that remain unclear, but it is well understood that cytochrome P450 is pivotal in camalexin biosynthesis and that this phytoalexin plays a major role in plant defense mechanisms.[57]

Cytochromes P450 are largely responsible for the synthesis of the jasmonic acid (JA), a common hormonal defenses against abiotic and biotic stresses for plant cells. For example, a P450, CYP74A is involved in the dehydration reaction to produce an insatiable allene oxide from hydroperoxide.[58] JA chemical reactions are critical in the presence of biotic stresses that can be caused by plant wounding, specifically shown in the plant, Arabidopsis. As a prohormone, jasmonic acid must be converted to the JA-isoleucine (JA-Ile) conjugate by JAR1 catalysation in order to be considered activated. Then, JA-Ile synthesis leads to the assembly of the co-receptor complex compo`sed of COI1 and several JAZ proteins. Under low JA-Ile conditions, the JAZ protein components act as transcriptional repressors to suppress downstream JA genes. However, under adequate JA-Ile conditions, the JAZ proteins are ubiquitinated and undergo degradation through the 26S proteasome, resulting in functional downstream effects. Furthermore, several CYP94s (CYP94C1 and CYP94B3) are related to JA-Ile turnover and show that JA-Ile oxidation status impacts plant signaling in a catabolic manner.[52] Cytochrome P450 hormonal regulation in response to extracellular and intracellular stresses is critical for proper plant defense response. This has been proven through thorough analysis of various CYP P450s in jasmonic acid and phytoalexin pathways.

Cytochrome P450 aromatic O-demethylase, which is made of two distinct promiscuous parts: a cytochrome P450 protein (GcoA) and three domain reductase, is significant for its ability to convert Lignin, the aromatic biopolymer common in plant cell walls, into renewable carbon chains in a catabolic set of reactions. In short, it is a facilitator of a critical step in Lignin conversion.

## P450s in biotechnology

The remarkable reactivity and substrate promiscuity of P450s have long attracted the attention of chemists.[59] Recent progress towards realizing the potential of using P450s towards difficult oxidations have included: (i) eliminating the need for natural co-factors by replacing them with inexpensive peroxide containing molecules,[60] (ii) exploring the compatibility of P450s with organic solvents,[61] and (iii) the use of small, non-chiral auxiliaries to predictably direct P450 oxidation.[citation needed]

## InterPro subfamilies

InterPro subfamilies:

* Cytochrome P450, B-class InterPro: IPR002397
* Cytochrome P450, mitochondrial InterPro: IPR002399
* Cytochrome P450, E-class, group I InterPro: IPR002401
* Cytochrome P450, E-class, group II InterPro: IPR002402
* Cytochrome P450, E-class, group IV InterPro: IPR002403
* Aromatase

Clozapine, imipramine, paracetamol, phenacetin Heterocyclic aryl amines Inducible and CYP1A2 5-10% deficient oxidize uroporphyrinogen to uroporphyrin (CYP1A2) in heme metabolism, but they may have additional undiscovered endogenous substrates. are inducible by some polycyclic hydrocarbons, some of which are found in cigarette smoke and charred food.

These enzymes are of interest, because in assays, they can activate compounds to carcinogens. High levels of CYP1A2 have been linked to an increased risk of colon cancer. Since the 1A2 enzyme can be induced by cigarette smoking, this links smoking with colon cancer.[62]

## See also

* Steroidogenic enzyme
* Cytochrome P450 oxidoreductase deficiency
* CYP11 family
* Cytochrome P450 engineering

## References

1. ↑ "Human cytochromes P450: evolution and cDNA-directed expression". Environmental Health Perspectives 98: 81–85. November 1992. doi:10.1289/ehp.929881. PMID 1486867.
2. ↑ 2.0 2.1 "Cytochrome P450". InterPro. http://www.ebi.ac.uk/interpro/entry/IPR001128.
3. ↑ 3.0 3.1 "The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans". Current Drug Metabolism 3 (6): 561–597. December 2002. doi:10.2174/1389200023337054. PMID 12369887.
4. ↑ "The first virally encoded cytochrome p450". Journal of Virology 83 (16): 8266–8269. August 2009. doi:10.1128/JVI.00289-09. PMID 19515774.
5. ↑ The Ubiquitous Roles of Cytochrome P450 Proteins: Metal Ions in Life Sciences. New York: Wiley. 2007. ISBN 978-0-470-01672-5.
6. ↑ "Cytochrome P450 diversity in the tree of life". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1866 (1): 141–154. January 2018. doi:10.1016/j.bbapap.2017.05.003. PMID 28502748.
7. ↑ "The cytochrome p450 homepage". Human Genomics (University of Tennessee) 4 (1): 59–65. October 2009. doi:10.1186/1479-7364-4-1-59. PMID 19951895.
8. ↑ "NCBI sequence viewer". https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&id=3915660.
9. ↑ "The cytochrome p450 homepage". Human Genomics 4 (1): 59–65. October 2009. doi:10.1186/1479-7364-4-1-59. PMID 19951895.
10. ↑ "Progress in tracing the evolutionary paths of cytochrome P450". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1814 (1): 14–18. January 2011. doi:10.1016/j.bbapap.2010.08.008. PMID 20736090.
11. ↑ "Electron transfer proteins of cytochrome P450 systems". Adv. Mol. Cell Biol.. Advances in Molecular and Cell Biology 14: 29–55. 1996. doi:10.1016/S1569-2558(08)60339-2. ISBN 9780762301133. https://www.science.co.il/hi/pub/Electron-transfer-proteins-of-cytochrome-P450-systems.pdf.
12. ↑ [1] PROSITE consensus pattern for P450
13. ↑ 13.0 13.1 "Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes". Chemical Reviews 104 (9): 3947–3980. September 2004. doi:10.1021/cr020443g. PMID 15352783.
14. ↑ "High-resolution crystal structure of cytochrome P450cam". Journal of Molecular Biology 195 (3): 687–700. June 1987. doi:10.1016/0022-2836(87)90190-2. PMID 3656428.
15. ↑ "Spin state control of the hepatic cytochrome P450 redox potential". Biochemical and Biophysical Research Communications 90 (3): 925–932. October 1979. doi:10.1016/0006-291X(79)91916-8. PMID 228675.
16. ↑ 16.0 16.1 16.2 "Cytochrome P450 compound I: capture, characterization, and C-H bond activation kinetics". Science 330 (6006): 933–937. November 2010. doi:10.1126/science.1193478. PMID 21071661. Bibcode: 2010Sci...330..933R.
17. ↑ 17.0 17.1 Cytochrome P450: structure, mechanism, and biochemistry (3rd ed.). New York: Kluwer Academic/Plenum Publishers. 2005. ISBN 978-0-306-48324-0.
18. ↑ "A brief history of carbon monoxide and its therapeutic origins". Nitric Oxide 111-112: 45–63. June 2021. doi:10.1016/j.niox.2021.04.001. PMID 33838343.
19. ↑ "Membrane position of ibuprofen agrees with suggested access path entrance to cytochrome P450 2C9 active site". The Journal of Physical Chemistry A 115 (41): 11248–11255. October 2011. doi:10.1021/jp204488j. PMID 21744854. Bibcode: 2011JPCA..11511248B.
20. ↑ 20.0 20.1 "P450 Table". 8 April 2021. http://drnelson.uthsc.edu/human.P450.table.html.
21. ↑ doctorfungus > Antifungal Drug Interactions Content Director: Russell E. Lewis, Pharm.D. Retrieved on Jan 23, 2010
22. ↑ "Cytochrome p450 and chemical toxicology". Chemical Research in Toxicology 21 (1): 70–83. January 2008. doi:10.1021/tx700079z. PMID 18052394. (Metabolism in this context is the chemical modification or degradation of drugs.)
23. ↑ "The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells". Biochemical Pharmacology 81 (3): 432–441. February 2011. doi:10.1016/j.bcp.2010.11.002. PMID 21070748.
24. ↑ "Carbamazepine: Watch for Many Potential Drug Interactions". Pharmacy Times. https://www.pharmacytimes.com/publications/issue/2008/2008-02/2008-02-8414.
25. ↑ "Interactions between grapefruit juice and cardiovascular drugs". American Journal of Cardiovascular Drugs 4 (5): 281–297. 2004. doi:10.2165/00129784-200404050-00002. PMID 15449971.
26. ↑ Zeratsky K (2008-11-06). "Grapefruit juice: Can it cause drug interactions?". Ask a food & nutrition specialist. MayoClinic.com. http://www.mayoclinic.com/health/food-and-nutrition/AN00413.
27. ↑ "Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort". Toxicology 217 (2–3): 194–205. January 2006. doi:10.1016/j.tox.2005.09.010. PMID 16271822.
28. ↑ "An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies". Phytomedicine 11 (2–3): 98–104. February 2004. doi:10.1078/0944-7113-00379. PMID 15070158.
29. ↑ "Drug interactions with smoking". American Journal of Health-System Pharmacy 64 (18): 1917–1921. September 2007. doi:10.2146/ajhp060414. PMID 17823102.
30. ↑ "Inhibition of human liver cytochrome P450 by star fruit juice". Journal of Pharmacy & Pharmaceutical Sciences 10 (4): 496–503. 2007. doi:10.18433/j30593. PMID 18261370.
31. ↑ "Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress". Clinical Pharmacology and Therapeutics 64 (2): 144–149. August 1998. doi:10.1016/S0009-9236(98)90147-3. PMID 9728894.
32. ↑ "Tributyltin pollution on a global scale. An overview of relevant and recent research: impacts and issues.". WWF UK. http://assets.wwf.no/downloads/tbt_global_review_wwf_uk_oct_2006.pdf.
33. ↑ "Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components". Drug Metabolism and Disposition 31 (11): 1391–1397. November 2003. doi:10.1124/dmd.31.11.1391. PMID 14570772.
34. ↑ "Diagram of the pathways of human steroidogenesis". WikiJournal of Medicine 1 (1). 2014. doi:10.15347/wjm/2014.005. ISSN 2002-4436.
35. ↑ "Update on autosomal recessive congenital ichthyosis: mRNA analysis using hair samples is a powerful tool for genetic diagnosis". Journal of Dermatological Science 79 (1): 4–9. July 2015. doi:10.1016/j.jdermsci.2015.04.009. PMID 25982146.
36. ↑ Nelson D (2003). Cytochromes P450 in humans. Retrieved May 9, 2005.
37. ↑ "The cytochrome P450 genesis locus: the origin and evolution of animal cytochrome P450s". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 368 (1612): 20120474. February 2013. doi:10.1098/rstb.2012.0474. PMID 23297357.
38. ↑ "The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome". Developmental Biology 300 (1): 366–384. December 2006. doi:10.1016/j.ydbio.2006.08.066. PMID 17097629.
39. ↑ "Aflatoxin B1 in poultry: toxicology, metabolism and prevention". Research in Veterinary Science 89 (3): 325–331. December 2010. doi:10.1016/j.rvsc.2010.04.011. PMID 20462619.
40. ↑ "Metabolism of aflatoxin B1 in turkey liver microsomes: the relative roles of cytochromes P450 1A5 and 3A37". Toxicology and Applied Pharmacology 254 (3): 349–354. August 2011. doi:10.1016/j.taap.2011.05.010. PMID 21616088.
41. ↑ "Dissecting the insecticide-resistance- associated cytochrome P450 gene Cyp6g1". Pest Management Science 64 (6): 639–645. June 2008. doi:10.1002/ps.1567. PMID 18338338.
42. ↑ "Pyrethroid activity-based probes for profiling cytochrome P450 activities associated with insecticide interactions". Proceedings of the National Academy of Sciences of the United States of America 110 (49): 19766–19771. December 2013. doi:10.1073/pnas.1320185110. PMID 24248381. Bibcode: 2013PNAS..11019766I.
43. ↑ "The preponderance of P450s in the Mycobacterium tuberculosis genome". Trends in Microbiology 14 (5): 220–228. May 2006. doi:10.1016/j.tim.2006.03.002. PMID 16581251.
44. ↑ "Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis". Nature Biotechnology 21 (5): 526–531. May 2003. doi:10.1038/nbt820. PMID 12692562.
45. ↑ "Identification of constitutive and herbicide inducible cytochromes P-450 in Streptomyces griseolus". Archives of Microbiology (Springer Science+Business) 149 (5): 406–412. 1988. doi:10.1007/bf00425579. ISSN 0302-8933. Bibcode: 1988ArMic.149..406O.
46. ↑ "Investigating conservation of the albaflavenone biosynthetic pathway and CYP170 bifunctionality in streptomycetes". The FEBS Journal 279 (9): 1640–1649. May 2012. doi:10.1111/j.1742-4658.2011.08447.x. PMID 22151149.
47. ↑ "CYP105-diverse structures, functions and roles in an intriguing family of enzymes in Streptomyces". Journal of Applied Microbiology 117 (6): 1549–1563. December 2014. doi:10.1111/jam.12662. PMID 25294646.
48. ↑ "Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium". The Journal of Biological Chemistry 261 (16): 7160–7169. June 1986. doi:10.1016/S0021-9258(17)38369-2. PMID 3086309.
49. ↑ "Flavocytochrome P450 BM3 and the origin of CYP102 fusion species". Biochemical Society Transactions 34 (Pt 6): 1173–1177. December 2006. doi:10.1042/BST0341173. PMID 17073779.
50. ↑ "Cloning of a potential cytochrome P450 from the archaeon Sulfolobus solfataricus". FEBS Letters 384 (3): 235–239. April 1996. doi:10.1016/0014-5793(96)00322-5. PMID 8617361.
51. ↑ "Biochemical basis for the activity and selectivity of oral antifungal drugs". British Journal of Clinical Practice. Supplement 71: 41–46. September 1990. PMID 2091733.
52. ↑ 52.0 52.1 "Impacts of diversification of cytochrome P450 on plant metabolism". Biological & Pharmaceutical Bulletin 35 (6): 824–832. 2012. doi:10.1248/bpb.35.824. PMID 22687470.
53. ↑ "Unusual P450 reactions in plant secondary metabolism". Archives of Biochemistry and Biophysics. P450 Catalysis Mechanisms 507 (1): 194–203. March 2011. doi:10.1016/j.abb.2010.09.026. PMID 20920462.
54. ↑ "Functional genomics of P450s". Annual Review of Plant Biology 54 (1): 629–667. 2003-01-01. doi:10.1146/annurev.arplant.54.031902.134840. PMID 14503006.
55. ↑ "The cytochrome P450 superfamily: Key players in plant development and defense" (in en). Journal of Integrative Agriculture 14 (9): 1673–1686. 2015-09-01. doi:10.1016/S2095-3119(14)60980-1. ISSN 2095-3119.
56. ↑ "Cytochromes P450 CYP94C1 and CYP94B3 catalyze two successive oxidation steps of plant hormone Jasmonoyl-isoleucine for catabolic turnover". The Journal of Biological Chemistry 287 (9): 6296–6306. February 2012. doi:10.1074/jbc.M111.316364. PMID 22215670.
57. ↑ "Role of Cytochrome P450 Enzymes in Plant Stress Response". Antioxidants 9 (5): 454. May 2020. doi:10.3390/antiox9050454. PMID 32466087.
58. ↑ "Canvas Login". https://login.canvas.uw.edu/wayf.
59. ↑ "Progress towards the easier use of P450 enzymes". Molecular BioSystems 2 (10): 462–469. October 2006. doi:10.1039/b607001a. PMID 17216026.
60. ↑ "Replacement of natural cofactors by selected hydrogen peroxide donors or organic peroxides results in improved activity for CYP3A4 and CYP2D6". ChemBioChem 7 (6): 916–919. June 2006. doi:10.1002/cbic.200600006. PMID 16671126.
61. ↑ "CYP3A4 activity in the presence of organic cosolvents, ionic liquids, or water-immiscible organic solvents". ChemBioChem 8 (10): 1189–1197. July 2007. doi:10.1002/cbic.200700128. PMID 17526062.
62. ↑ "Effects of tobacco smoking and nicotine on cancer treatment". Pharmacotherapy 32 (10): 920–931. October 2012. doi:10.1002/j.1875-9114.2012.01117. PMID 23033231.

## Further reading

* "Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm". Journal of Clinical Pharmacology 46 (3): 353–372. March 2006. doi:10.1177/0091270005285200. PMID 16490812.
* "Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery". Trends in Pharmacological Sciences 20 (11): 432–438. November 1999. doi:10.1016/S0165-6147(99)01382-6. PMID 10542439.
* "Cytochrome P450 Mediated Drug and Carcinogen Metabolism using Monoclonal Antibodies". https://home.ccr.cancer.gov/metabolism/mab1.htm.
* "Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19". Drug Metabolism and Disposition 29 (11): 1410–1423. November 2001. PMID 11602516. http://dmd.aspetjournals.org/content/29/11/1410.
* "Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins". Drug Metabolism Reviews 26 (1–2): 165–183. 1994. doi:10.3109/03602539409029789. PMID 8082563.
* "A passion for P450s (rememberances of the early history of research on cytochrome P450)". Drug Metabolism and Disposition 31 (12): 1461–1473. December 2003. doi:10.1124/dmd.31.12.1461. PMID 14625342.

## External links

* "Directory of P450-containing Systems". International Centre for Genetic Engineering and Biotechnology. 2009-01-09. http://www.icgeb.org/~p450srv/.
* "Human Cytochrome P450 (CYP) Allele Nomenclature Committee". Karolinska Institutet. 2008-09-04. https://www.pharmvar.org/.
* "Cytochrome P450 database". Nucleic Acids Research. 2010. http://bioinformatics.charite.de/supercyp/.
* "pharmacokinetic interaction table". Sigaroudi & Vollbrecht. 2019. http://www.kisch.ch/.
* "Cytochrome P450 drug interaction table". Indiana University-Purdue University Indianapolis. 2007. http://medicine.iupui.edu/flockhart/.

* v
* t
* e

Proteins: hemeproteins

Globins|

| Hemoglobin|

| Subunits|

| Alpha locus on 16:|

* α
* HBA1
* HBA2
* pseudo
* ζ
* HBZ
* θ
* HBQ1
* μ
* HBM

|

Beta locus on 11:|

* β
* HBB
* δ
* HBD
* γ
* HBG1
* HBG2
* ε
* HBE1

Tetramers|

| stages of development:|

| Embryonic|

* HbE Gower 1 (ζ2ε2)
* HbE Gower 2 (α2ε2)
* HbE Portland I (ζ2γ2)
* HbE Portland II (ζ2β2)

|

Fetal|

* HbF/Fetal (α2γ2)
* HbA (α2β2)

Adult|

* HbA (α2β2)
* HbA2 (α2δ2)
* HbF/Fetal (α2γ2)

pathology:|

* HbH (β4)
* Barts (γ4)
* HbS (α2βS2)
* HbC (α2βC2)
* HbE (α2βE2)

Compounds|

* Carboxyhemoglobin
* Carbaminohemoglobin
* Oxyhemoglobin/Deoxyhemoglobin
* Sulfhemoglobin

Other human|

* Glycated hemoglobin
* Methemoglobin

Nonhuman|

* Chlorocruorin
* Erythrocruorin

Other|

| human:|

* Myoglobin
* Metmyoglobin
* Neuroglobin
* Cytoglobin

|

plant:|

* Leghemoglobin

Other|

* Cytochrome
* Cytochrome b
* Cytochrome P450
* Hemocyanin
* Methemalbumin

see also disorders of globin and globulin proteins

* v
* t
* e

Cytochromes, oxygenases: cytochrome P450 (EC 1.14)

CYP1|

* A1
* A2
* B1

CYP2|

* A6
* A7
* A13
* B6
* C8
* C9
* *3
* *13
* C18
* C19
* D6
* E1
* F1
* J2
* R1
* S1
* U1
* W1

CYP3 (CYP3A)|

* A4
* A5
* A7
* A43

CYP4|

* A11
* A22
* B1
* F2
* F3
* F8
* F11
* F12
* F22
* V2
* X1
* Z1

CYP5-20|

* CYP5 (A1)
* CYP6 (G1)
* CYP7 (A1, B1)
* CYP8 (A1, B1)
* CYP11 (A1, B1, B2)
* CYP17 (A1)
* CYP19 (A1)
* CYP20 (A1)

CYP21-51|

* CYP21 (A2)
* CYP22 (A1)
* CYP24 (A1)
* CYP26 (A1, B1, C1)
* CYP27 (A1, 25-Hydroxyvitamin D3 1-alpha-hydroxylase

CYP101-120|

* CYP101
* CYP102A1
* CYP107A1
* CYP119A1

CYP201-300|

* CYP255A

CYP301-320|

* CYP305M2
* Halloween genes ( CYP302A1, CYP306A1, CYP307A1, CYP307A2, CYP314A1, CYP315A1)

* v
* t
* e

Enzymes

Activity|

* Active site
* Binding site
* Catalytic triad
* Oxyanion hole
* Enzyme promiscuity
* Catalytically perfect enzyme
* Coenzyme
* Cofactor
* Enzyme catalysis

Regulation|

* Allosteric regulation
* Cooperativity
* Enzyme inhibitor
* Enzyme activator

Classification|

* EC number
* Enzyme superfamily
* Enzyme family
* List of enzymes

Kinetics|

* Enzyme kinetics
* Eadie–Hofstee diagram
* Hanes–Woolf plot
* Lineweaver–Burk plot
* Michaelis–Menten kinetics

Types|

* EC1 Oxidoreductases (list)
* EC2 Transferases (list)
* EC3 Hydrolases (list)
* EC4 Lyases (list)
* EC5 Isomerases (list)
* EC6 Ligases (list)
* EC7 Translocases (list)

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Cytochrome P450. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Cytochrome_P450&oldid=412357"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template